Treatment with or without bevacizumab as a first‐line and maintenance therapy for advanced non‐squamous non‐small cell lung cancer: A retrospective study
Abstract Background Pemetrexed and bevacizumab as monotherapies, or in combination, have been approved for maintenance therapy following platinum‐based induction in patients with advanced nonsquamous non‐small cell lung cancer (NSCLC). The differences in the benefits of bevacizumab for treatment dur...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-07-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13469 |